Autoimmune hemolytic anemia following mf59-adjuvanted influenza vaccine administration: A report of two cases

Annals of Pharmacotherapy

Volumn 45, Issue 1, 2011, Pages

  Montagnani, Sabrina ^a   Tuccori, Marco ^b   Lombardo, Giuseppe ^c   Testi, Arianna ^c   Mantarro, Stefania ^a   Ruggiero, Elisa ^b   Blandizzi, Corrado ^b  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

^c Hospital of Empoli   (Italy)

Author keywords

Autoimmune hemolytic anemia; MF59 adjuvanted influenza vaccine

Indexed keywords

ACETYLSALICYLIC ACID; CORTICOSTEROID; INFLUENZA VACCINE; MIFAMURTIDE; RAMIPRIL;

ABDOMINAL PAIN; AGED; ARTICLE; ASTHENIA; AUTOIMMUNE HEMOLYTIC ANEMIA; BLOOD TRANSFUSION; CASE REPORT; CLINICAL FEATURE; FEMALE; HUMAN; LABORATORY TEST; LOW DRUG DOSE; PRIORITY JOURNAL; REHYDRATION; VIROLOGY;

ABDOMINAL PAIN; ADJUVANTS, IMMUNOLOGIC; AGED; AGED, 80 AND OVER; ANEMIA, HEMOLYTIC, AUTOIMMUNE; ARTHRALGIA; ASTHENIA; FATAL OUTCOME; FEMALE; FEVER; HUMANS; INFLUENZA VACCINES; LOWER EXTREMITY; MUSCLE WEAKNESS; POLYSORBATES; SQUALENE; TREATMENT OUTCOME;

EID: 78751499828     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P480     Document Type: Article

References (22)

1. Podda A, Del Giudice G. MF59-adjuvanted vaccine: increased immunogenicity with an optimal safety profile. Exp Rev Vacc 2003;2:197-203.
2. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006;354:1343-51.
3. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001;19:2673-80.
4. Dias PJ, Gopal S. Refractory thrombotic thrombocytopenic purpura following influenza vaccination. Anaesthesia 2009;64:444-6.
5. Brown RC, Blecher TE, French EA, Toghill PJ. Thrombotic thrombocytopenic purpura after influenza vaccination (letter). Br Med J 1973; 861:303.
6. World Health Organization (WHO). International drug monitoring: the role of national centres. Report of a WHO meeting (498). Geneva: World Health Organization, 1972.
7. Schultze V, D'Agosto V, Wack A, Novichi D, Zorn J, Hennig R. Safety of MF59 adjuvant. Vaccine 2008;26:3209-22.
8. Sanford-Driscoll M, Knodel LC. Induction of hemolytic anemia by nonsteroidal antiinflammatory drugs. Drug Intell Clin Pharm 1986;20:925-34.
9. Product information. Altace tablets (ramipril). http://www.accessdata. fda.gov/drugsatfda-docs/label/2009/022021s006lbl.pdf (accessed 2010 Sept 1).
10. Kohm AP, Fuller KG, Miller SD. Mimicking the way to autoimmunity: an evolving theory of sequence and structural homology. Trends Microbiol 2003;11:101-5.
11. Agmon-Levin N, Kivity S, Shoenfeld Y. Influenza vaccine and autoimmunity. Isr Med Assoc J 2009;11:183-5.
12. Molina V, Shoenfeld Y. Infection, vaccines and other environmental triggers of autoimmunity. Autoimmunity 2005;38:235-45.
13. Haber P, DeStefano F, Angulo FJ, et al. Guillain-Barrè syndrome following influenza vaccination. JAMA 2004;24:2478-81.
14. Blunberg S, Biefang D, Kantrowitz FG. A possible association between influenza vaccination and small-vessel vasculitis. Arch Intern Med 1980; 140:847-8.
15. Vial T, Laine V, Delcombel M, et al. Vasculitis after anti-influenza vaccination. Report of 5 cases. Therapie 1990;45:509-12.
16. Schattner A. Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. Vaccine 2005;23:3876-86.
17. Podda A, Del Giudice G. MF59 adjuvant emulsion. New generation vaccines. 3rd ed. New York: Marcel Dekker, 2004:225-36.
18. Ott G, Radhakrishnan R, Fang JH, Hora M. The adjuvant MF59: a 10- year perspective. In: O'Hagan D, ed. Vaccine adjuvants: preparation methods and research protocols. Totowa, NJ: Humana Press, 2000:211-28.
19. Asa PB, Wilson RB, Garry RF. Antibodies to squalene in recipients of anthrax vaccine. Exp Mol Pathol 2002;320:1363-7.
20. Allison AC. Squalene and squalene emulsions as adjuvants. Methods 1999;19:87-93.
21. Mosca F, Tritto E, Muzzi A, et al. Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci U S A 2008;105:10501-6.
22. Pellegrini M, Nicolay U, Lindert K, Groth N, Della Cioppa G. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine 2009;27:6959-65.